key: cord-0707775-arnpu7h4
authors: Ono‐Uruga, Yukako; Ikeda, Yasuo; Matsubara, Yumiko
title: Platelet production using adipose‐derived mesenchymal stem cells: Mechanistic studies and clinical application
date: 2020-12-21
journal: J Thromb Haemost
DOI: 10.1111/jth.15181
sha: d3bdd8db52cde01841e20107ef94b5b0943d09ea
doc_id: 707775
cord_uid: arnpu7h4

Megakaryocytes (MKs) are platelet progenitor stem cells found in the bone marrow. Platelets obtained from blood draws can be used for therapeutic applications, especially platelet transfusion. The needs for platelet transfusions for clinical situation is increasing, due in part to the growing number of patients undergoing chemotherapy. Platelets obtained from donors, however, have the disadvantages of a limited storage lifespan and the risk of donor‐related infection. Extensive effort has therefore been directed at manufacturing platelets ex vivo. Here, we review ex vivo technologies for MK development, focusing on human adipose tissue‐derived mesenchymal stem/stromal cell line (ASCL)‐based strategies and their potential clinical application. Bone marrow and adipose tissues contain mesenchymal stem/stromal cells that have an ability to differentiate into MKs, which release platelets. Taking advantage of this mechanism, we developed a donor‐independent system for manufacturing platelets for clinical application using ASCL established from adipose‐derived mesenchymal stem/stromal cells (ASCs). Culture of ASCs with endogenous thrombopoietin and its receptor c‐MPL, and endogenous genes such as p45NF‐E2 leads to MK differentiation and subsequent platelet production. ASCs compose heterogeneous cells, however, and are not suitable for clinical application. Thus, we established ASCLs, which expand into a more homogeneous population, and fulfill the criteria for mesenchymal stem cells set by the International Society for Cellular Therapy. Using our ASCL culture system with MK lineage induction medium without recombinant thrombopoietin led to peak production of platelets within 12 days, which may be sufficient for clinical application.

Bone marrow cells called megakaryocytes (MKs) are large-sized cells with DNA polyploidy that form and release platelets during terminal thrombopoiesis. [1] [2] [3] Platelets have an essential role in the process of physiologic hemostasis. Thrombocytopenia, caused by an insufficient number of platelets, may be inherited or acquired, for example during chemotherapy. [4] [5] [6] Patients with severe thrombocytopenia often require platelet transfusions. The demand for platelet transfusions continues to increase globally. In both Europe and the United States more than 4.5 million donor-derived platelet units are transfused annually. 7 Donor-derived platelet concentrates have a F I G U R E 1 A, A schematic going from adipocytes to megakaryocytes (MKs) to platelets. There are two steps to obtain adipose-derived mesenchymal stem/stromal cell line (ASCL)-derived platelets. First, ASCL is established from adipose tissues by the upside-down method. When ASCL-derived platelets are needed, ASCL is cultured in megakaryocyte induction (MKLI) medium in the absence of recombinant thrombopoietin (TPO), described in the section "Production of MKs and platelets from MSCs/stromal cells," with a bioreactor. For the yield of ASCL-derived platelets, 1.5 × 10 10 ASCLs were obtained from 10 g of adipose tissue, and ASCL release 1 to 10 platelets. Thus, 100 g of adipose-tissue is enough to obtain 10 11 ASCL-derived platelets. ASC, adipose-derived mesenchymal stem/stromal cells; PLT, platelet. B, A schematic going from adipose-derived stem cells, iPSCs, and HSCs to MKs and platelets. Platelets reported to be differentiated from ASCs, 31 iPSCs, 14, 24 and HSCs. 13 C, Endogenous TPO secreted via interactions between transferrin and its receptor, CD71, is involved in platelet differentiation from mesenchymal stem/stromal cells. Binding of transferrin to its receptor CD71 leads to the production of endogenous TPO. Interactions between TPO and its receptor c-MPL contribute to MK differentiation and subsequent platelet production. MKLI, MK lineage-induction medium in the absence of recombinant TPO limited storage lifespan and carry a risk for bacterial infection. Novel approaches for supplying an adequate quantity of MKs and platelets will be needed to meet future demands.

Progress in technology has promoted regenerative medicine, and advanced ex vivo platelet production ( Figure 1A ,B). [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Several kinds of stem cells, such as hematopoietic stem cells (HSCs), pluripotent stem cells, as well as endometrial stromal cells and nuclear factor, erythroid-derived 2 45KDa subunit (p45NF-E2), Maf K-,and Maf Gtransfected fibroblasts can be induced to differentiate into MKs and platelets by culturing them with MK induction medium and recombinant thrombopoietin (TPO). [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Although MKs and platelets are easily produced from HSCs using this method, the proliferative abilities in vitro are unsatisfactory. Platelet yields are critical for establishing an ideal system for manufacturing platelets. More than 10 11 platelets are used per transfusion in an adult patient. MKs proliferate little or not at all without gene transduction, and thus the development of an expandable MK cell source is critical for platelet manufacture.

A system using induced pluripotent stem cells (iPSCs) has been most often used as starting cells to produce MKs and subsequent platelets. iPSCs have a proliferative activity in in vitro culture systems.

Several groups have developed a system for platelet manufacture using iPSCs, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and the technology for manufacturing MKs and subsequent platelets is rapidly developing. Table 1 shows recent reports of MK and platelet production. Nakamura et al reported how iPSCs need undergo additional gene manipulation for efficient amount of iPSC-derived MKs: to obtain the expandable MK cell line, immortalized megakaryocyte progenitor cell lines (imMKCL), iPSCs were transfected with BMI1 proto-oncogene, polycomb ring finger (BMI1) and BCL2 like (BCL-XL) for the inhibition of cell senescence, and MYC proto-oncogene, bHLH transcription factor (c-MYC) for the promotion of cell proliferation. 14 One imMKCL released three to 10 platelets. Moreau et al generated long-term MKs after iPSCs were transfected with GATA binding protein 1 (GATA1) and Fli-1 proto-oncogene, ETS transcription factor(Fli1), and TAL bHLH transcription factor 1, erythroid differentiation factor (TAL1). 21 They found that these MKs release five platelets per cell.

Within the bone marrow environment, platelets released from MKs are regulated by various factors of bone marrow niche, such as blood flow and extracellular matrix. Bioreactor for manufacturing platelets was developed based on bone marrow niche, 26 with two groups using their expandable MKs along with bioreactors to produce large number of platelets for clinical application (Table 1) : Ito et al demonstrated that they can achieve 70 to 80 platelets from im-MKCLs 14 using turbulence in a bioreactor. 24 Shepherd et al reported high platelet release of 30 platelets per MK using long-term MKs and a structurally graded collagen scaffold within a flow bioreactor system. 25 Moreover, iPSCs offer the ability to manipulate the nature of the resultant iPSC-derived MKs that can be of benefit in the transfusion of challenging patients. These include a targeted genetic manipulation to obtain human leukocyte antigen-lacking platelets and platelets with recipient-specific HPA-2. 12 As an alternative to iPSC as a starting cell source, we demonstrated that MKs and platelets could be produced from mesenchymal cells isolated from adipose and bone marrow tissues. [27] [28] [29] [30] [31] [32] Mesenchymal cells, which comprise mesenchymal stem cells (MSCs), preadipocytes, and stromal cells, can be obtained by centrifuging bone marrow or adipose tissues. Large amounts of adipose tissue are readily available. The stromal vascular fraction of mesenchymal cells is difficult to assess because of the nonhomogeneous nature of isolated cell fractions leading to the implantation of endothelial cells as well as different immune cell types. 33 We attempted to elucidate the mechanisms by which MKs and platelets are produced from mesenchymal cells and to identify the cell population responsible for their differentiation. We initially used commercially available preadipocytes.

We then established a human adipose tissue-derived mesenchymal stem/stromal cell line (ASCL, Figure 1A , Table 1 ), and characterized these cells as MSCs according to the definition of the International Society for Cellular Therapy (ISCT). 33, 34 A large-scale platelet manufacturing strategy has also been developed to be used with subcutaneous adipose-derived mesenchymal cells as cell source for platelet differentiation. Next, we focus on the advantages and limitations of the use of this line to produce human MKs and platelets, and their potential clinical application.

Stem cells are able to regulate both self-replication and differentiate into many different cell types. Stem cells comprise at least two types, embryonic stem cells and adult stem cells. MSCs, a type of adult stem cell, are nonhematopoietic multipotent stem cells that can be collected from bone marrow, adipose tissue, umbilical cord, and dental pulp. 35 MSCs have a critical role in immunosuppression, inflammation resolution, and tissue repair. 36, 37 The ISCT defined the minimal criteria for human MSCs according to three major characteristics as follows: the cells are adherent to plastic in culture with standard medium; most (>95%) of the cells express CD73, CD90, and CD105; and very few (<2%) of the cells express pan-leucocyte antigen CD45, hematopoietic and endothelial progenitor marker CD34, monocyte/macrophage antigen CD14 or CD11b, B lymphocyte antigen CD79α or CD19, or class II antigen human leukocyte antigen-DR.

Finally, the cells must be capable of differentiating into adipocytes, osteoblasts, and chondrocytes. 33, 34 Intensive studies aimed at establishing clinical applications for MSCs derived from bone marrow and adipose tissue have been performed. 38, 39 The application of bone marrow-derived MSCs, as a regenerative medicine for patients with graft-versus-host disease, an immune-related disease, has been reported. 40 

The molecular mechanisms underlying MK differentiation and platelet production are not fully understood. We previously studied a mechanism of platelet production using HSCs and embryonic stem cells in vitro using OP9, a mouse bone marrow stroma cell line, as a feeder cell. 28, 41 OP9 cells were established from macrophage colony-stimulating factor-deficient osteopetrotic mice. 41 OP9 cells have different cell lineages from hematopoietic cells and are reported to be preadipocytes and MSCs. 42 They are commonly used as feeder cells for the differentiation of stem cells, including embryonic stem cells and iPSCs, into hematopoietic cells. 41, 43, 44 When using MK lineage-induction (MKLI) medium, 27 

The lineage commitment from HSCs is mainly regulated by transcription factors and cytokines. We first planned to identify the factors that determine MK and thrombopoiesis induction. We observed that MKs and platelets are produced from the preadipocyte cell line 3T3-L1, but not its parent cell line, fibroblast cell line 3T3. 30 To screen for factors involved in MK induction, we compared the gene expression profiles of 3T3 cells and 3T3-L1 cells.

Gene expression levels were examined on the basis of quantitative RT-PCR threshold cycle values. mRNA expression of CCAAT enhancer binding protein alpha (CEBP alpha), an important factor for adipocyte differentiation, and p45NF-E2 was detected in 3T3-L1 preadipocyte cells. Neither factor was detected in 3T3 fibroblast cells. 11 We next evaluated whether adult human dermal fibroblasts can be induced to differentiate into MKs and platelets by 

We found that MSCs/stromal cells express p45NF-E2, and gene expression levels increased during MK differentiation from MSCs/ stromal cells. 28, 32 We also observed p45NF-E2 gene expression in MKs, 28, 32 but not in embryonic stem cells. 28 Further, OP9 cells transfected with p45NF-E2 produced more MKs and platelets, suggesting an important role of p45NF-E2 in their production. MSC/ stromal cells also express genes, such as GATA2 and Fli1, involved in the production of MKs and platelets. 28 

Cytokines and transcription factors have essential roles in the determining cell fate for MK lineages. TPO is an important cytokine that regulates the lineage commitment of MKs. [45] [46] [47] [48] [49] Recombinant TPO is commonly used in culture systems to induce a MK-rich population from stem cells, including HSCs, embryonic stem cells, and iPSCs.

TPO production by the liver has been reported. 45, 49 Although TPO production from MSCs/stromal cells is less well known, we found that OP9 cells and 3T3-L1 cells express TPO message. 28 Although TPO gene expression level increased during MK differentiation from these MSC/stromal cells, there was little TPO secretion from these cells cultured in maintenance media so that MK differentiation normally depends on endogenous TPO. [45] [46] [47] [48] [49] We, therefore, investigated whether TPO endogenously released from MKs is sufficient to induce the differentiation of human adipose-derived mesenchymal stem/stromal cells (ASCs) into MKs and subsequent platelet production by culturing ASCs cultured in MKLI medium in the absence of recombinant TPO. TPO was secreted into the supernatant during MK differentiation from ASCs using MKLI medium in the absence of recombinant TPO, but was not detected in the supernatant from ASCs cultured in ASC maintenance We investigated the mechanism of TPO secretion from ASCs during MK differentiation. Various components of the MKLI medium were examined to analyze the factor(s) responsible for TPO production. ASCs were cultured in each of the components of the MKLI medium in the absence of recombinant TPO. TPO secretion was only observed in the supernatant from cells cultured with transferrin-containing media. 31 On the basis of this screening test,

we examined the effect of the transferrin receptor CD71 on TPO secretion. Using the small interference RNA-CD71, an anti-CD71 antibody, and CD71-positive/negative cells isolated by fluorescence-activated cell sorting, we explored the role of CD71 in the secretion of TPO from ASCs cultured with transferrin-containing MKLI medium in the absence of recombinant TPO. We observed that TPO was secreted in a transferrin dose-dependent manner.

The TPO secretion levels and number of MKs produced by CD71positive ASCs were significantly higher than those produced by CD71-negative ASCs. Thus, endogenous TPO binds to its receptor c-MPL on ASCs, which is involved in the production of ASC-derived MKs and platelets. 31 Interactions between transferrin and CD71

induce the secretion of endogenous TPO during MK differentiation from ASCs ( Figure 1C ). These finding provide novel insights into how ASCs differentiate into MKs and platelets. We also suggest the existence of a TPO-independent mechanism because MKs were also derived from CD71-negative ASCs. 31 MK production from CD71-negative ASCs was observed in the presence of antic-MPL antibody. The frequency of MKs from CD71-negative ASCs was lower than that from CD71-positive ASCs, 31 supporting that there might be a TPO-independent mechanism for MK production from ASCs.

ASCs are candidate starting cells for manufacturing platelets for clinical application. Gene transfer is not necessary for inducing the differentiation of ASCs into MKs and platelets. The application of endogenous TPO promotes the differentiation of ASCs into platelets. Although ASCs are advantageous for manufacturing platelets, they are heterogeneous and may not be an efficient source of donor-independent platelets. We therefore established human ASCL as a cell source for large-scale platelet production ( Figure 1A , Table 1 ). These cells meet the ISCT criteria for

MSCs. 33, 34 For the proliferation activity of ASCL, cells proliferate fast in the first 30 days, and reach a plateau after 60 days of culture. 32 To analyze the genetic karyotype stability, the ASCL were cultured for at least 60 days, and no abnormalities was observed in the ASCL. 32 To characterize the differentiated cells, we performed flow cy- (Table 1) . As compared with the imMKCL and LT-fokMK using a bioreactor (as described previously), released number of platelets is lower in ASCL-MKs than those iPS-derived MKs (Table 1) . Thus, the period of ASCL expansion would need to be longer than iPSC/imMKCL and LT-fokMK to obtain similar number of ASCL platelets with imMKCL-derived platelets and LT-fokMK-derived platelets.

Platelet function studies were performed on ASCL platelets compared to donor-derived platelet concentrates obtained from the Japanese Red Cross. The ASCL platelets and platelet concentrates exhibited no spontaneous aggregation in the resting stage. Application of various agonists (eg, ADP, collagen, ristocetin, epinephrine) induced the aggregation of the ASCL platelets and platelet concentrates. 32 We examined PAC-1 binding and also P-selectin surface exposure, both markers of platelet activation, on the two sources of platelets in similar agonist stimulation studies. Although baseline PAC1 binding and surface exposure of P-selectin tended to be higher on ASCL platelets than on platelet concentrates, both increased more on the ASCL platelets, supporting potential clinical utility upon transfusion. These (higher) functions might be partially associated with CD90 expression on ASCL platelets, 32 as described previously, and CD90 is involved in cell adhesion. Platelet adhesion has a critical role in the function.

On the other hand, one possible way to reduce the hyperactivity of the ASCL platelets for infusion may be to decrease the number of infused cells. We are studying a monitoring system to optimize the use of ASCL platelets for infusion.

Also, we observed that the increased activation of ASCL platelets was regulated by aspirin. The thromboxane B 2 secretion levels under stimulation in ASCL platelets were lower than that in platelet concentrates, and the levels were decreased in the presence of aspirin, suggesting that baseline activity of ASCL platelets may be druggable.

Of importance is that, on transfusion into irradiation-induced thrombocytopenic, immunodeficient NOD/SCID gamma mice, the ASCL platelets and donor-derived platelets had similar half-lives and provided similar improved hemostatic function when assessed ex vivo in an automated microchip flow chamber system (Total Thrombus-formation Analysis System, Fujimori Kogyo Co., Ltd). 52, 53 ASCL platelets collected on day 12 were used for the functional studies. 32 We do not have functional data of platelets collected on day 4 and day 20, and it is important to examine function of platelets collected on day 4 and day 20.

These studies also need to be repeated in a more clinically relevant model, perhaps using nonhuman primates, but suggest that the mild increased in baseline activity of ASCL platelets may be of limited clinical import.

In summary, we review the use of MSCs to generate MKs and platelets and describe their potential clinical use as well as compared MSC-derived MKs and platelets to donor-and iPSC-derived cells.

The 

Yukako Ono-Uruga wrote the portion for platelets from mesenchymal stem cell line. Yasuo Ikeda wrote the portion for iPS-derived platelets. Yumiko Matsubara wrote and edited the manuscript , and supervised to prepare the manuscript.

Delivering new insight into the biology of megakaryopoiesis and thrombopoiesis

From hematopoietic stem cells to platelets

Platelet transfusion: an update on challenges and outcomes

Origins of platelet transfusion therapy

Platelet transfusions

Manufacturing blood ex vivo: a futuristic approach to deal with the supply and safety concerns

In vitro megakaryocyte production and platelet biogenesis: state of the art

Ex vivo production of platelets from stem cells

Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf

Current status of blood 'pharming': megakaryoctye transfusions as a source of platelets

Humaninduced pluripotent stem cell-derived blood products: state of the art and future directions

Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells

Towards the manufacture of megakaryocytes and platelets for clinical application

Stem cells, megakaryocytes, and platelets

Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGFpromoted structures that concentrate hematopoietic progenitors

Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells

Human endometrial stromal stem cells differentiate into megakaryocytes with the ability to produce functional platelets

Scalable generation of universal platelets from human induced pluripotent stem cells

Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming

Platelet generation in vivo and in vitro

Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale

Turbulence activates platelet biogenesis to enable clinical scale ex vivo production

Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: enhancing production and purity

In vitro generation of platelets: where do we stand?

Culture of megakaryocytes and platelets from subcutaneous adipose tissue and a preadipocyte cell line

OP9 bone marrow stroma cells differentiate into megakaryocytes and platelets

Generation of megakaryocytes and platelets from human subcutaneous adipose tissues

Generation of megakaryocytes and platelets from preadipocyte cell line 3T3-L1, but not the parent cell line 3T3, in vitro

Human adipose tissue-derived stromal cells can differentiate into megakaryocytes and platelets by secreting endogenous thrombopoietin

Megakaryocytes and platelets from novel human adipose-derived mesenchymal stem cell line

Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis

Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy?

Comparison of human mesenchymal stem cells derived from dental pulp, bone marrow, adipose tissue, and umbilical cord tissue by gene expression

Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair

The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm

Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients

Current applications of adipose-derived stem cells and their future perspectives

Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease

Generation of lymphohematopoietic cells from embryonic stem cells in culture

Characterization of OP9 as authentic mesenchymal stem cell line

Orderly hematopoietic development of induced pluripotent stem cells via Flk-1(+) hemoangiogenic progenitors

In vitro generation of HSC-like cells from murine ESCs/iPSCs by enforced expression of LIM-homeobox transcription factor Lhx2

Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl

Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin

The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production

Purification and characterization of thrombopoietin

Thrombopoietin from beginning to end

GATA-1: one protein, many partners

The role of the GATA2 transcription factor in normal and malignant hematopoiesis

A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions

A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process

Platelet production using adipose-derived mesenchymal stem cells: Mechanistic studies and clinical application